Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission: Reflections on a series of cases
Gastroenterol Hepatol. 2024 Oct;47(8):867-868.
doi: 10.1016/j.gastrohep.2023.07.004.
Epub 2023 Aug 8.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.
- 2 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.
- 3 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España. Electronic address: [email protected].
No abstract available
MeSH terms
-
Adult
-
Colitis, Ulcerative / drug therapy
-
Crohn Disease / drug therapy
-
Drug Therapy, Combination
-
Female
-
Gastrointestinal Agents / administration & dosage
-
Gastrointestinal Agents / therapeutic use
-
Humans
-
Inflammatory Bowel Diseases / drug therapy
-
Infliximab* / administration & dosage
-
Infliximab* / therapeutic use
-
Male
-
Middle Aged
-
Remission Induction*
Substances
-
Infliximab
-
Gastrointestinal Agents